Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „across“
Suchtreffer
Begriffe & Kennungen
Adcetris · 4.8 · In the pooled dataset of ADCETRIS as monotherapy across HL, sALCL and CTCL studies (SG035-0003, SG035-0004, SG
Eintrag öffnenAlecensa · 4.8 · Adverse reactions of bilirubin elevations were reported in 25.9 % of the patients treated with Alecensa across
Eintrag öffnenAlecensa · 4.8 · Hepatotoxicity Across clinical trials, three patients had a documented drug-induced liver injury (including tw
Eintrag öffnenAlecensa · 4.8 · Interstitial lung disease (ILD) / pneumonitis Across clinical trials, ILD/pneumonitis occurred in 1.7 % of pat
Eintrag öffnenAmlodipine / Valsartan Mylan · 4.8 · The mean incidence of peripheral oedema evenly weighted across all doses was 5.1 % with the amlodipine/valsart
Eintrag öffnenArexvy · 4.8 · Across the three studies, these adverse reactions were usually mild or moderate in intensity and resolved with
Eintrag öffnenAvastin · 4.8 · Across all clinical trials, mucocutaneous haemorrhage has been seen in up to 50% of Avastin-treated patients.
Eintrag öffnenAvastin · 4.8 · Across clinical trials, 8 cases of PRES have been reported. Two of the eight cases did not have radiological c
Eintrag öffnenAvastin · 4.8 · Across clinical trials, the following Grade 3 and 4 (NCI-CTCAE v.3) laboratory abnormalities occurred in patie
Eintrag öffnenAvastin · 4.8 · Haemorrhage (see section 4.4) In clinical trials across all indications the overall incidence of NCI-CTCAE v.3
Eintrag öffnenAvastin · 4.8 · In clinical trials across indications, the overall incidence of venous thromboembolic reactions ranged from 2.
Eintrag öffnenAvastin · 4.8 · The most frequently observed adverse reactions across clinical trials in patients receiving Avastin were hyper
Eintrag öffnenAwiqli · 4.8 · Across the ONWARDS trials, most hypoglycaemic episodes were observed day 2-4 after the weekly administration.
Eintrag öffnenBiktarvy · 4.8 · The assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies with Biktarv
Eintrag öffnenBimzelx · 4.8 · Across indications, no clinically meaningful impact on clinical response was associated with anti- bimekizumab
Eintrag öffnenBlincyto · 4.8 · The type and frequency of adverse reactions were similar across different paediatric subgroups (gender, age an
Eintrag öffnenBrilique · 4.8 · The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, ge
Eintrag öffnenBrilique · 4.8 · The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, ge
Eintrag öffnenBrilique · 4.8 · The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, ge
Eintrag öffnenCabazitaxel Accord · 4.8 · Discontinuation of treatment due to adverse reactions occurred with similar frequencies across the 3 studies (
Eintrag öffnen